News

Oncocyte Presents DetermaIO™ Data in Podium Presentation at ESMO World Congress on Gastrointestinal Cancer 2022

Researchers conducted exploratory analysis to find an optimized IO score after validation of original established endpoint was presented at the…

2 years ago

Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

- FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will…

2 years ago

Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

- FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will…

2 years ago

Alignment Healthcare to Announce Second Quarter 2022 Financial Results and Host Conference Call Thursday, Aug. 4, 2022

ORANGE, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (Nasdaq: ALHC), a tech-enabled…

2 years ago

Protega Pharmaceuticals™ LLC Announces Commercialization of RoxyBond™ (oxycodone hydrochloride) Tablets CII in the U.S.

RoxyBond is the first and only immediate-release opioid medication with FDA-approved labeling describing abuse-deterrent properties.1 PRINCETON, N.J., July 06, 2022…

2 years ago

Femasys Inc. Announces Existing Board Member Charles Larsen as Chairperson of the Board

Mr. Larsen brings over 40 years of medical device industry experience and skills strongly aligned with the Company’s strategy to…

2 years ago

NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation

BELTSVILLE, Md., July 06, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel,…

2 years ago

Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients

- Phase 3 Clinical Study Met Primary and Key Secondary Endpoints - - Primary Endpoint: Sabizabulin Treatment Showed Statistically Significant…

2 years ago

Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System Disorders

TORONTO, July 06, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"),…

2 years ago

Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test

ACTON, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company…

2 years ago